Journal article
Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells
eLife, Vol.5(JULY), e14740
07/19/2016
DOI: 10.7554/eLife.14740
PMCID: PMC4982760
PMID: 27434671
Abstract
The DNA repair protein RAD52 is an emerging therapeutic target of high importance for BRCA-deficient tumors. Depletion of RAD52 is synthetically lethal with defects in tumor suppressors BRCA1, BRCA2 and PALB2. RAD52 also participates in the recovery of the stalled replication forks. Anticipating that ssDNA binding activity underlies the RAD52 cellular functions, we carried out a high throughput screening campaign to identify compounds that disrupt the RAD52-ssDNA interaction. Lead compounds were confirmed as RAD52 inhibitors in biochemical assays. Computational analysis predicted that these inhibitors bind within the ssDNA-binding groove of the RAD52 oligomeric ring. The nature of the inhibitor-RAD52 complex was validated through an in silico screening campaign, culminating in the discovery of an additional RAD52 inhibitor. Cellular studies with our inhibitors showed that the RAD52-ssDNA interaction enables its function at stalled replication forks, and that the inhibition of RAD52-ssDNA binding acts additively with BRCA2 or MUS81 depletion in cell killing.
Details
- Title: Subtitle
- Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells
- Creators
- Sarah R Hengel - Department of Biochemistry, University of Iowa, Iowa City, United StatesEva Malacaria - Department of Environment and Health, Section of Experimental and Computational Carcinogenesis, Istituto Superiore di Sanita, Rome, ItalyLaura Folly da Silva Constantino - Division of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, United StatesFletcher E Bain - Department of Biochemistry, University of Iowa, Iowa City, United StatesAndrea Diaz - Department of Biochemistry, University of Iowa, Iowa City, United StatesBrandon G Koch - Department of Biochemistry, University of Iowa, Iowa City, United StatesLiping Yu - NMR Core Facility, Carver College of Medicine, University of Iowa, Iowa City, United StatesMeng Wu - High Throughput Screening Facility, University of Iowa, Iowa City, United StatesPietro Pichierri - Department of Environment and Health, Section of Experimental and Computational Carcinogenesis, Istituto Superiore di Sanita, Rome, ItalyM Ashley Spies - Division of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, United StatesMaria Spies - Department of Biochemistry, University of Iowa, Iowa City, United States
- Resource Type
- Journal article
- Publication Details
- eLife, Vol.5(JULY), e14740
- DOI
- 10.7554/eLife.14740
- PMID
- 27434671
- PMCID
- PMC4982760
- NLM abbreviation
- Elife
- ISSN
- 2050-084X
- eISSN
- 2050-084X
- Publisher
- England
- Grant note
- R01 GM097373 / NIGMS NIH HHS P30 CA086862 / NCI NIH HHS S10 RR029274 / NCRR NIH HHS
- Language
- English
- Date published
- 07/19/2016
- Academic Unit
- Pharmacy; Core Research Facilities; Pharmaceutical Sciences and Experimental Therapeutics; Orthopedics and Rehabilitation; Radiation Oncology; Biochemistry and Molecular Biology; Medicine Administration; Medicinal and Natural Products Chemistry
- Record Identifier
- 9984024550302771
Metrics
18 Record Views